A Multicenter, Single arm, Open-label, Expansion Study of ONO-7702 and ONO-7703 in Patients with BRAF V600E-mutant Metastatic Colorectal Cancer(ONO-7702/7703-02E)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 09 Feb 2022

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Binimetinib (Primary) ; Cetuximab (Primary) ; Encorafenib (Primary) ; Irinotecan (Primary)
Indications Colorectal cancer
Focus Adverse reactions; Expanded access; Therapeutic Use
Sponsors Ono Pharmaceutical

09 Feb 2022 Planned number of patients changed from 50 to 100.
22 Jan 2022 Results presented at the 2022 Gastrointestinal Cancers Symposium
21 Dec 2021 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com